Findings
VTE
SECONDARY
In this secondary analysis from a cluster randomized, crossover trial that included 23 458 patients, there was no significant difference found in mortality within 90 days for patients allocated to aspirin compared with patients allocated to receive enoxaparin for VTE prophylaxis.